Last reviewed · How we verify
RO6839921
At a glance
| Generic name | RO6839921 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. (PHASE1)
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO6839921 CI brief — competitive landscape report
- RO6839921 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI